Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension.

X
Trial Profile

A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren (Primary) ; Losartan
  • Indications Essential hypertension; Hypertension; Left ventricular hypertrophy
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms ALLAY; ASPIRE-HIGHER
  • Sponsors Novartis
  • Most Recent Events

    • 09 May 2011 Additional trial locations (Argentina, Colombia, Finland, Italy, Russia, Spain, Sweden) added as reported by ClinicalTrials.gov
    • 15 Jun 2009 Pharmcodynamic results presented at the 19th European Meeting on Hypertension, 2009.
    • 03 Feb 2009 Resulted reported in Circulation, 3 February 2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top